Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Core Points - Liang Hongjun has resigned from his positions as Vice Chairman, Director, and General Manager of Jiukang Biological due to work relocation [1] - Following the resignation, Liang will no longer hold any position within the company [1] - During the interim period of the General Manager vacancy, Chairman Zou Zuojuan will assume the responsibilities of the General Manager until a new appointment is made [1]

格隆汇9月5日丨九强生物(300406.SZ)公布，公司董事会于近日收到副董事长、董事、总经理梁红军先 生提交的书面辞职报告，梁红军先生因工作调动原因辞去公司副董事长、董事、董事会专门委员会及总 经理职务。辞去上述职务后，梁红军先生不再担任公司任何职务，其在公司子公司的任职，已按照有关 规定同步办理离职手续，之后不再担任公司子公司任何职务。 ...

公司及董事会对梁红军先生在任职期间为公司经营发展和公司董事会工 作作出的重要贡献表示衷心感谢！ 特此公告。 北京九强生物技术股份有限公司董事会 2025年9月5日 北京九强生物技术股份有限公司 关于副董事长、总经理离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、 误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）董事会于近日收 到副董事长、董事、总经理梁红军先生提交的书面辞职报告，梁红军先生因 工作调动原因辞去公司副董事长、董事、董事会专门委员会及总经理职务。 辞去上述职务后，梁红军先生不再担任公司任何职务，其在公司子公司的任 职，已按照有关规定同步办理离职手续，之后不再担任公司子公司任何职务。 截至本公告披露日，梁红军先生未持有公司股份。梁红军先生原定任期 至公司第五届董事会届满之日，即自 2023 年 9 月 22 日至 2026 年 9 月 21 日 止，其任职期间不存在未履行的承诺。 根据《中华人民共和国公司法》《公司章程》等相关规定，梁红军先生 的辞职未导致公司董事会成员人数低于法定最低人数，不会影响公司董事会 的正常运行，其辞职报告自送达 ...

Core Viewpoint - Beijing Jiukang Biotechnology Co., Ltd. announces the suspension of the conversion of its convertible bonds "Jiukang Convertible Bonds" (bond code: 123150) during the rights distribution period from August 28, 2025, to September 4, 2025, and will resume conversion on September 5, 2025 [1] Summary by Relevant Sections - The company guarantees the authenticity, accuracy, and completeness of the information disclosed, ensuring no false records, misleading statements, or significant omissions [1] - The suspension of the bond conversion is in accordance with the regulations outlined in the prospectus for the issuance of convertible bonds to unspecified objects [1] - Bondholders are advised to pay attention to the resumption of conversion on the first trading day after the rights distribution registration date [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于九强转债恢复转股的提示性公告 特此公告。 北京九强生物技术股份有限公司董事会 2025 年 9 月 4 日 1、债券代码：123150 ；债券简称：九强转债 2、恢复转股时间：自 2025 年 9 月 5 日起恢复转股 北京九强生物技术股份有限公司（以下简称"公司"）因实施 2025 年半年度权益 分派，根据《北京九强生物技术股份有限公司创业板向不特定对象发行可转换公司债 券募集说明书》及相关规定，公司可转换公司债券（债券代码：123150 ；债券简称： 九强转债 ）自 2025 年 8 月 28 日至本次权益分派股权登记日（2025 年 9 月 4 日）止暂 停转股。具体内容详见公司于 2025 年 8 月 27 日披露的《关于实施权益分派期间九强 转债暂停转股的提示性公告》（公告编号：2025-065）。 根据规定，"九强转债" 将于本次权益分派股权登记日后的第一个交易日即 2025 年 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

人民财讯9月3日电，九强生物（300406）9月3日晚间公告，公司近日收到北京市药监局颁发的《医疗器 械注册证》，产品名称为肝素结合蛋白测定试剂盒(胶乳免疫比浊法)，该试剂盒用于体外定量测定人血 浆中肝素结合蛋白(HBP)的含量。 ...

Core Viewpoint - The company has received a medical device registration certificate for its Heparin Binding Protein (HBP) assay kit, which is expected to enhance its product portfolio and core competitiveness, although it will not have a significant impact on recent operations and performance [1]. Group 1 - The product is a Heparin Binding Protein assay kit using the latex immunoturbidimetric method [1]. - The registration certificate was issued by the Beijing Drug Administration, with the registration number 京械注准20252400796 [1]. - The registration falls under Class II medical devices and is valid until August 31, 2030 [1]. Group 2 - The acquisition of this registration certificate enriches the company's product categories [1]. - It is expected to have a positive impact on the company's future development [1]. - However, it is noted that there will be no major impact on the company's recent operations and performance [1].

| 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 肝素结合蛋白测定 试剂盒（胶乳免疫比 | 京 械 注 准 20252400796 | Ⅱ | 自批准之日起有效期 至 2030 年 08 月 31 日 | 本试剂盒用于体外定量 测定人血浆中肝素结合 | | | 浊法） | | | | 蛋白（HBP）的含量。 | 上述产品医疗器械注册证的取得，丰富了公司产品类别，有利于增强公 司的核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业 绩不会产生重大影响，敬请投资者注意风险。 特此公告。 北京九强生物技术股份有限公司 董事会 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 证券代码：300406 | 证券简称：九强生物 公告编号：2025-0 ...